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Abstract: 
Introduction: Mycobacterium tuberculosis (Mtb) are classified as acid-fast Gram-positive bacteria due to their lack 
of a typical outer cell membrane. Contagious tuberculosis spreads through the air. Objectives of the study: The main 
objective of the study is to analyze the interaction of antimicrobial peptides as a treatment of tuberculosis. 
Methodology of the study: This cross-sectional study was conducted at Services Hospital Lahore during February 
2018 till July 2018. The data was collected from 100 patients of both genders. Those patients who suffered from TB 
and visited the OPD of the hospital included in this study. In this analyzes we compare the different drugs of TB which 
are available in the market as compared to antimicrobial peptides. A reasonable approach to find new therapeutics 
against the high number of MDR and XDR strains is to find molecules having a different killing mechanism. Results: 
The data was collected from 100 TB patients. The mean age of the selected patients was 50.98±4.56 years.  Peptide 
concentrations of 1, 10 and 100 μg/ml, 10-fold serial concentrations were used. After 7 days incubation with peptides, 
the CFU/ml of each sample was calculated compared with day 0. The samples treated with D1 or D5 at 100 μg/ml 
had dramatic reductions in CFU/ml. eptide D5 increased the anti-tuberculosis activity by about 5.7-fold compared to 
D4, which is due to a valine to lysine substitution at position 16. Conclusion: It is concluded that Many AMPs have 
good or moderate activities against mycobacteria, however, in general the activities are lower as compared to the 
activities found against other Gram-negative or Gram-positive bacteria. 
Corresponding author:  
Dr. Iram Hassan, 
Services Institute of Medical Sciences, Lahore 
 
 
 
 
Please cite this article in press Iram Hassan et al., A Comprehensive Study On Interaction Of Antimicrobial 
Peptides As A Treatment Of Tuberculosis., Indo Am. J. P. Sci, 2019; 06(05). 
 
QR code 
 
 
IAJPS 2019, 06 (05), 10633-10635                     Iram Hassan et al                       ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 10634 
 
 
INTRODUCTION: 
Mycobacterium tuberculosis (Mtb) are classified as 
acid-fast Gram-positive bacteria due to their lack of a 
typical outer cell membrane. Contagious tuberculosis 
spreads through the air. According to World Health 
Organization’s report: more than 2 billion people, one-
third of the world’s population, are infected with M. 
tuberculosis [1]. In 2008, 9.4 million new cases of 
tuberculosis (TB) were reported including 1.4 million 
cases among people living with human 
immunodeficiency virus (HIV). There were 1.8 
million people who died from TB in 2008, including 
500,000 people with HIV [2]. TB is a leading killer of 
HIV patients. 5% of all TB cases involve multi-drug 
resistant (MDR) Mtb, which is a form of Mtb that is 
difficult and expensive to treat and fails to respond to 
standard first-line drugs [3]. The emergence and rapid 
spread of MDR Mtb strains represents a worldwide 
health care problem. M. tuberculosis within host cells 
is surrounded by a capsule outside the bacterial wall 
and membrane which represents a passive barrier 
impeding the diffusion of molecules towards inner 
parts of the envelope. The capsule consists of a 
complex mixture of polysaccharides, proteins, lipids 
and enzymes including pro-teases and lipidases all of 
which may participate to the active resistance of the 
bacterium to the hosts’ microbicidal mechanisms [4]. 
Since, the lipid-rich cell wall structure of 
mycobacteria makes the cell surface hydrophobic, the 
permeability to anti-tuberculosis drugs is reduced. It is 
believed that the resistance to anti-mycobacterial 
drugs is mainly due to the peculiar properties of the 
mycobacterial cell envelope [5]. 
 
Tuberculosis (TB) is still one of the most deadliest 
communicable diseases worldwide. In 2013, an 
estimated 9 million people developed TB and 1.5 
million people died from TB. The global trend is a 
decrease of incidence, prevalence, and mortality. 
However, with the emergence of multi-drug resistant 
(MDR) and extensively drug resistant 
(XDR) Mycobacterium tuberculosis (Mtb) strains, 
new classes of anti-mycobacterial agents are urgently 
needed. MDR strains are resistant at least against 
isoniazid (INH) and rifampicin (RIF) and XDR strains 
are resistant against INH, RIF, fluoroquinolone, and 
one of amikacin, kanamycin, or capreomycin [6]. 
 
Objectives of the study 
The main objective of the study is: 
 To analyze the interaction of antimicrobial 
peptides as a treatment of tuberculosis. 
 
METHODOLOGY OF THE STUDY: 
This cross sectional study was conducted at Services 
Hospital Lahore during February 2018 till July 2018. 
The data was collected from 100 patients of both 
genders. Those patients who suffered from TB and 
visited the OPD of the hospital included in this study. 
In this analyzes we compare the different drugs of TB 
which are available in the market as compared to 
antimicrobial peptides. A reasonable approach to find 
new therapeutics against the high number of MDR and 
XDR strains is to find molecules having a different 
killing mechanism.  On the other hand, the assays as 
well as the conditions used are quite diverse. All the 
collected data was analyzed using SPSS version 21.0. 
 
RESULTS: 
The data was collected from 100 TB patients. The 
mean age of the selected patients was 50.98±4.56 
years.  Peptide concentrations of 1, 10 and 100 μg/ml, 
10-fold serial concentrations were used. After 7 days 
incubation with peptides, the CFU/ml of each sample 
was calculated compared with day 0. The samples 
treated with D1 or D5 at 100 μg/ml had dramatic 
reductions in CFU/ml. eptide D5 increased the anti-
tuberculosis activity by about 5.7-fold compared to 
D4, which is due to a valine to lysine substitution at 
position 16. Our lead compound, peptide D1 had a 2.8-
fold improvement in anti-tuberculosis activity 
compared to that of D4. 
Table 01: Biological Activity of peptides against M. tuberculosis 
Peptide 
Name 
Hemolytic 
Activity 
Anti-Tuberculosis 
Activity to H37Rv 
Strain 
Therapeutic Index to 
H37Rv Strain 
Anti-Tuberculosis 
Activity to MDR 
Strain 
HC50
a Foldb MICc Foldb HC50/MICd Fold
b MICc 
μg/ml μg/ml μg/ml 
D1 421.5 120 70.7 2.8 6.0 333 57 
D2 83 24 83.7 2.4 1.0 56.0 72 
D3 14 4 109.2 1.8 0.13 7.2 100 
D4 3.5 1 200 1.0 0.018 1.0 Ie 
D5 47 13 35.2 5.7 1.3 72.0 49 
L-LL37 43.5 12 Ie — Ie — Ie 
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D-LL37 125 36 200 1.0 0.63 35.0 Ie 
DISCUSSION: 
Several of the peptides designed from first principles 
had improved activity relative to LL37. In our studies 
we observed that only D-LL37 exhibits growth 
inhibitory activity against H37Rv, but does not appear 
to kill M.tuberculosis at concentration below 100 
μg/mL. Careful examination of data from others 
reveals that our results with L-LL37 are consistant 
with previous studies. Lactoferricins are naturally 
occurring peptides, formed by the cleavage of the 
highly cationic N1 terminal domain of the iron-
binding protein lactoferrin [7]. All peptides showed an 
antimycobacterial activity with LD50 values between 
10 and 40 μM. The stronger activity was found in the 
bovine-based peptides. A significant difference in the 
activity against three different M. avium strains could 
not be found [8]. 
 
PR-39, a proline–arginine rich AMP isolated from pig 
intestine, has activity against drug-susceptible as well 
as MDR clinical isolates of Mtb. At 50 μg/ml 80% 
growth inhibition of Mtb H37Rv could be achieved.  
Martineau et al. investigated the role of iron 
concentration on the activity of lipocalin 2. Lipocalin 
2–induced suppression of Mtb CFU was greater in 
iron-depleted broth than in iron-replete broth (150 μM 
Fe) with values of 60% versus 45%, respectively [9].  
Azurophil granule protein (AZP) are active against M. 
smegmatis and M. bovis BCG [73]. Jena et al. 
investigated this mixture of molecules and 
identified elastase and lysozyme to be important for 
mycobacterial killing [10]. 
 
CONCLUSION: 
It is concluded that Many AMPs have good or 
moderate activities against mycobacteria, however, in 
general the activities are lower as compared to the 
activities found against other Gram-negative or Gram-
positive bacteria. One big advantage of AMPs is that 
the active ones showed almost same activities 
against Mtb strains being sensitive against 
conventional antibiotics and also against MDR and 
XDR strains.  
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